Production (Stage)
NRx Pharmaceuticals, Inc.
NRXP
$3.27
$0.3311.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 13.28% | 7.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.11% | 20.25% | |||
| Operating Income | -3.11% | -20.25% | |||
| Income Before Tax | 39.28% | -459.33% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 39.28% | -459.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 39.28% | -459.33% | |||
| EBIT | -3.11% | -20.25% | |||
| EBITDA | -3.10% | -20.30% | |||
| EPS Basic | 54.67% | -401.01% | |||
| Normalized Basic EPS | 49.78% | -98.88% | |||
| EPS Diluted | 54.12% | -401.01% | |||
| Normalized Diluted EPS | 49.78% | -98.88% | |||
| Average Basic Shares Outstanding | 33.95% | 11.64% | |||
| Average Diluted Shares Outstanding | 33.95% | 11.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||